Scarica l'app Stockscreener
1.15
0.43%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.15
Aprire:
$1.17
Volume 24 ore:
509.74K
Relative Volume:
0.29
Capitalizzazione di mercato:
$210.87M
Reddito:
$137.74M
Utile/perdita netta:
$-27.97M
Rapporto P/E:
-7.1875
EPS:
-0.16
Flusso di cassa netto:
$-9.61M
1 W Prestazione:
+6.94%
1M Prestazione:
-12.50%
6M Prestazione:
-12.50%
1 anno Prestazione:
-54.71%
Intervallo 1D:
$1.14
$1.1867
Intervallo di 1 settimana:
$1.13
$1.33
Portata 52W:
$0.9999
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
Nome
Heron Therapeutics Inc
Settore
Industria
Telefono
(858) 251-4400
Indirizzo
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.15 | 210.87M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.50 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.22 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
747.00 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.76 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
296.88 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2024-04-23 | Iniziato | CapitalOne | Overweight |
| 2024-03-13 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Buy |
| 2020-02-20 | Reiterato | Needham | Buy |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-04-05 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Reiterato | Mizuho | Buy |
| 2018-03-01 | Reiterato | Needham | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Outperform |
| 2017-09-27 | Iniziato | Northland Capital | Outperform |
| 2017-02-27 | Iniziato | Needham | Buy |
| 2016-10-26 | Iniziato | Aegis Capital | Buy |
| 2016-09-06 | Ripresa | Lake Street | Buy |
| 2016-05-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-10 | Iniziato | Lake Street | Buy |
| 2015-09-23 | Reiterato | Leerink Partners | Outperform |
| 2015-09-02 | Iniziato | BofA/Merrill | Buy |
| 2015-08-03 | Reiterato | Brean Capital | Buy |
| 2015-06-30 | Reiterato | JMP Securities | Mkt Outperform |
| 2015-06-19 | Reiterato | Leerink Partners | Outperform |
| 2014-08-07 | Iniziato | Noble Financial | Buy |
Mostra tutto
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
HC Wainwright Has Negative Forecast for HRTX FY2026 Earnings - MarketBeat
What is Northland Securities' Forecast for HRTX Q1 Earnings? - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
HRTX Should I Buy - Intellectia AI
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2025 Earnings Call Transcript - Insider Monkey
What is HC Wainwright's Estimate for HRTX Q1 Earnings? - MarketBeat
HRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target - TipRanks
Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment - MSN
Heron Therapeutics Q4 Earnings Call Highlights - MarketBeat
Heron Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HRTX) 2026-02-26 - Seeking Alpha
Key facts: Heron Therapeutics projects $173-$183M revenue by 2026; ZYNRELEF adoption rises; credit facilities expanded - TradingView
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Heron Therapeutics, Inc. Provides Earnings Guidance for the Year 2026 - marketscreener.com
Earnings call transcript: Heron Therapeutics Q4 2025 reports strong growth By Investing.com - Investing.com Canada
Heron Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
HRTX: 2025 net revenue rose 7.4% to $154.9M, with strong Acute Care growth and positive EBITDA - TradingView
HERON THERAPEUTICS ($HRTX) Releases Q4 2025 Earnings - Quiver Quantitative
Heron Therapeutics: Fourth Quarter Earnings Overview - Bitget
Heron Therapeutics: Q4 Earnings Snapshot - marketscreener.com
HERON THERAPEUTICS, INC. /DE/ SEC 10-K Report - TradingView
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results - The Manila Times
HRTX: 2025 net revenue rose 7.4% to $154.9M, driven by Acute Care growth and new CMS J-Codes - TradingView
Heron Therapeutics, Inc. (HRTX) Stock Analysis: A Biotech With A Potential 301% Upside - DirectorsTalk Interviews
Aug Sectors: Whats Heron Therapeutics Incs historical returnWeekly Profit Recap & Technical Pattern Based Signals - baoquankhu1.vn
Heron Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring A Potential Upside Of 258.13% - DirectorsTalk Interviews
Heron Therapeutics, Inc. $HRTX Shares Acquired by JW Asset Management LLC - MarketBeat
Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday - MarketBeat
Aug EndMonth: What are JOFF Fintech Acquisition Corp Debt Equity Composite Unitss growth leversMarket Trend Report & Verified Entry Point Detection - baoquankhu1.vn
MSN Money - MSN
Heron: Near The Bottom Of A Trading Range Despite Positives (NASDAQ:HRTX) - Seeking Alpha
Clearline Capital reports 6.7% Heron Therapeutics stake (HRTX) - Stock Titan
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - The Manila Times
Should I set a stop loss on Heron Therapeutics Inc.Dollar Strength & Entry Point Confirmation Signals - mfd.ru
Can Heron Therapeutics Inc. expand into new marketsWeekly Risk Report & Breakout Confirmation Trade Signals - mfd.ru
How does Heron Therapeutics Inc. compare to its peersJuly 2025 Weekly Recap & Community Consensus Trade Alerts - mfd.ru
How strong is Heron Therapeutics Inc. (AXD2) stock earnings growthJuly 2025 WrapUp & Safe Capital Growth Tips - mfd.ru
How resilient is Heron Therapeutics Inc. stock in market downturnsJuly 2025 Rallies & Free Accurate Trade Setup Notifications - mfd.ru
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden - simplywall.st
Is Heron Therapeutics Inc. impacted by rising rates2025 Market Outlook & Weekly Hot Stock Watchlists - mfd.ru
Is Heron Therapeutics Inc. stock a good dividend stock2025 Analyst Calls & Daily Technical Stock Forecast Reports - mfd.ru
New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics, Inc. (HRTX): Investor Outlook Reveals Potential 240.91% Upside - DirectorsTalk Interviews
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast - Defense World
Heron Therapeutics (NASDAQ:HRTX) Shares Pass Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Heron Therapeutics (HRTX) awards EVP new RSUs and PSUs - Stock Titan
Heron Therapeutics Inc Azioni (HRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Heron Therapeutics Inc Azioni (HRTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
0.14%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):